$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
乐伐替尼适用于分化型甲状腺癌患者的治疗
2025-10-19 11:44:20
Check Details
甲状腺癌靶向治疗药物仑伐替尼
2025-10-19 11:44:20
Check Details
乐伐替尼治疗甲状腺癌是否安全有效?
2025-10-19 11:44:20
Check Details
乐伐替尼改善分化型甲状腺癌无进展生存时间
2025-10-19 11:44:20
Check Details
日本患者队列分析:乐伐替尼治疗碘难治性甲状腺癌
2025-10-19 11:44:20
Check Details
乐伐替尼+依维莫司增强抗肿瘤活性——靶向肿瘤生长和血管生成
2025-10-19 11:44:20
Check Details
分化型甲状腺癌的靶向药物乐伐替尼
2025-10-19 11:44:20
Check Details
乐伐替尼 vs安慰剂治疗放射性碘难治性甲状腺癌
2025-10-19 11:44:20
Check Details
乐伐替尼治疗甲状腺癌优于安慰剂
2025-10-19 11:44:20
Check Details
乐伐替尼提高甲状腺癌患者无进展生存期
2025-10-19 11:44:20
Check Details
乐伐替尼治疗碘难治性分化型甲状腺癌2期试验结果
2025-10-19 11:44:20
Check Details
乐伐替尼可以治愈甲状腺癌吗?
2025-10-19 11:44:20
Check Details
1
2
...
8488
8489
8490
8491
8492
8493
8494
...
10209
10210
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Odevixibat: Targeting IBAT to Transform Cholestatic Liver Disease Treatment
2
A Precision FGFR Inhibitor for Cholangiocarcinoma
3
A Revolutionary Targeted Therapy for Hematological Malignancies
4
A New Option for Advanced Renal Cell Carcinoma Treatment
5
Trametinib (Mekinist): Precision MEK1/2 Inhibition Transforming Cancer Care Short Description:
6
Pirtobrutinib: A Novel BTK Inhibitor Offering Hope for Hematologic Cancer Patients Short Description:
7
Olaparib Plus Pembrolizumab Maintenance Therapy for Metastatic Pancreatic Cancer: Findings from the POLAR Phase II Basket Trial
8
Sacituzumab Govitecan: Trop-2 Targeted ADC Clinical Medication Guide
9
Fulvestrant (Faslodex) Breast Cancer Guide: Indications, Dosage and Safety Specifications
10
Avatrombopag (Doptelet) Dosage: Dose Adjustment and Medication Guidelines for Different Indications
11
Effects of Gilteritinib (Xospata) Discontinuation in Acute Myeloid Leukemia Treatment
12
Avatrombopag vs Hetrombopag: Full Comparison of TPO Receptor Agonists for Thrombocytopenia